After decades of research on immune checkpoints inhibitors (ICIs), the use of immunotherapies targeting programmed death-1 (PD-1), its ligand PD-L1 and cytotoxic T lymphocyte antigen 4 (CTLA4) have been reported to be effective in many cancer types. This evidence concerns the gene CTLA4 and cancer.